Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Score, Valuation & Financial Research

Polaryx Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PLYX

Polaryx Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 2.02. These figures are a research snapshot, not a buy or sell recommendation.

What Polaryx Therapeutics, Inc. Common Stock does

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Polaryx Therapeutics is a clinical-stage biotechnology company that generates no revenue from product sales. Its business model relies on raising capital through equity and debt financing to fund the research, development, and clinical trial activities for its pipeline of small molecule drug candidates targeting rare, pediatric lysosomal storage diseases.

Products and services

  • The company is developing a pipeline of orally available small molecule drug candidates, including PLX-200, PLX-300, and PLX-100, designed to address pathological mechanisms in rare, pediatric lysosomal storage diseases such as Krabbe disease and Sandhoff disease.

Customer types

Patients with rare, pediatric lysosomal storage diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and preclinical studies. Source
  • Contract Manufacturing Organizations (CMOs) — The company depends on third-party contract manufacturing organizations for the production of its drug candidates for clinical use. Source

Competitors and product-market comparisons

  • Companies developing treatments for CLN2 disease — The company faces competition from other biotechnology and pharmaceutical companies developing therapies for lysosomal storage diseases, including CLN2 disease. Source

Business strengths to evaluate

  • Focus on high unmet medical need in rare pediatric diseases Source
  • Orally available small molecule drug candidate pipeline Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source · Companies developing treatments for CLN2 disease

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PLYX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.02
Market capitalization:
100.69M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -6.85M
Free cash flow:
USD -3.94M
Cash:
USD 11.54M
Total debt:
USD 0.00
EPS:
USD -0.12

What stands out

  • Free cash flow is USD -3.94M, negative for the stored period.
  • The balance sheet shows USD 11.54M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 11.54M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PLYX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PLYX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PLYX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PLYX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of PLYX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research PLYX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.